# OnCo record esg401 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/esg401/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "esg401" ;
  schema:name "ESG401"@en ;
  schema:description "ESG401 is an experimental investigational agent whose form is not stated in the registry from Qilu Pharmaceutical in phase 3 trials for triple-negative breast cancer and HR-positive / HER2-negative breast cancer, with its target not yet stated publicly."@en ;
  schema:url <https://onco.cc/drugs/esg401/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=ESG401>, <https://www.qilu-pharma.com> ;
  onco:status "phase-3" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:companies <https://onco.cc/companies/qilu-pharmaceutical/> ;
  onco:trials <https://onco.cc/trials/nct06732323/>, <https://onco.cc/trials/nct06383767/> .